Bank of Montreal’s Sarepta Therapeutics SRPT Stock Holding History

Bank of Montreal’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,200	Closed	-$244K	–	4040
2026 Q1	$244K	Buy	+11,200	New	+$217K	﹤0.01%	2818
2025 Q4	–	Sell	-1,200	Closed	-$23.1K	–	3821
2025 Q3	$23.1K	Buy	+1,200	New	+$21.4K	﹤0.01%	3262
2019 Q1	–	Sell	-50,000	Closed	-$5.46M	–	4714
2018 Q4	$5.46M	Buy	+50,000	New	+$6.25M	0.01%	1035
2016 Q4	–	Sell	-55,700	Closed	-$3.42M	–	4183
2016 Q3	$3.42M	Sell	55,700 -76,600	-58%	-$2.32M	﹤0.01%	1257
2016 Q2	$2.52M	Buy	+132,300	New	+$2.45M	﹤0.01%	1389

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bank of Montreal's SRPT Position: Q2 2026 in Review

Bank of Montreal reduced its Sarepta Therapeutics (SRPT) stake by 61% in Q2 2026, selling an estimated $296K and leaving 10,185 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

Bank of Montreal first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $37.8M in Q1 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Bank of Montreal held 10,185 shares of Sarepta Therapeutics worth $183K as of Q2 2026.
Bank of Montreal sold 15,630 Sarepta Therapeutics shares in Q2 2026, an estimated $296K.
Sarepta Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #3042 holding.
Bank of Montreal first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
Bank of Montreal's Sarepta Therapeutics position peaked at $37.8M in Q1 2022.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.